ASHP therapeutic position statement on strict glycemic control in selected patients with insulin-dependent diabetes mellitus.
ASHP supports strict glycemic control in selected patients with IDDM on the basis of studies demonstrating that strict glycemic control delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy. Because of the increased risk of hypoglycemia, intensive treatment regimens may not be appropriate in patients with poor perception of hypoglycemic symptoms and those with a history of frequent, severe hypoglycemic episodes. The pharmacist can play a key role in implementing and monitoring this therapy by collaborating with other members of the health care team and by counseling patients.
D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D010593:Pharmaceutical Services; D012957:Societies, Pharmaceutical; D014481:United States
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin